BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its target price boosted by analysts at Royal Bank Of Canada from $13.00 to $14.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has an “outperform” rating on the biotechnology company’s stock. Royal Bank Of Canada’s price target suggests a potential upside of 37.86% from the company’s previous close.

A number of other equities research analysts have also recently commented on the stock. Wedbush decreased their target price on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Wall Street Zen cut shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Needham & Company LLC decreased their price objective on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Weiss Ratings restated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research note on Monday, June 1st. Finally, Cantor Fitzgerald upped their target price on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a report on Tuesday, June 30th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, BioCryst Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.78.

BioCryst Pharmaceuticals Stock Down 0.1%

BCRX traded down $0.01 during midday trading on Tuesday, reaching $10.15. The company had a trading volume of 1,522,312 shares, compared to its average volume of 5,192,985. The business has a 50-day moving average of $8.99 and a two-hundred day moving average of $8.35. BioCryst Pharmaceuticals has a 1 year low of $6.00 and a 1 year high of $10.94. The company has a market cap of $2.58 billion, a P/E ratio of -5.72 and a beta of 0.55.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). The company had revenue of $156.41 million for the quarter, compared to analysts’ expectations of $151.12 million. BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The firm’s quarterly revenue was up 7.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.20 earnings per share. On average, equities research analysts predict that BioCryst Pharmaceuticals will post -2.63 EPS for the current year.

Institutional Trading of BioCryst Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada increased its holdings in shares of BioCryst Pharmaceuticals by 2.4% in the first quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock worth $476,000 after purchasing an additional 1,458 shares during the last quarter. Cetera Investment Advisers lifted its position in shares of BioCryst Pharmaceuticals by 13.8% in the fourth quarter. Cetera Investment Advisers now owns 12,330 shares of the biotechnology company’s stock worth $96,000 after buying an additional 1,494 shares in the last quarter. Captrust Financial Advisors boosted its stake in BioCryst Pharmaceuticals by 7.4% during the second quarter. Captrust Financial Advisors now owns 22,105 shares of the biotechnology company’s stock valued at $198,000 after buying an additional 1,527 shares during the last quarter. Counterweight Ventures LLC boosted its stake in BioCryst Pharmaceuticals by 2.1% during the fourth quarter. Counterweight Ventures LLC now owns 95,384 shares of the biotechnology company’s stock valued at $744,000 after buying an additional 2,000 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in BioCryst Pharmaceuticals by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 2,115 shares in the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.